The Center for Image-Guided Animal Therapy is currently recruiting dogs with osteosarcoma for a clinical trial. Enrolled dogs will receive cryotherapy or immunotherapy prior to surgical amputation and chemotherapy. This clinical trial is funded by the Children’s Cancer Foundation, Swim Across America, and The National Institutes of Health National Cancer Institute. If your pet has osteosarcoma, please contact [email protected] or call 410-502-7325 for additional information.
Learn More: Clinical trial flier | Clinical trial details handout

The Center for Image-Guided Animal Therapy is currently recruiting dogs with brain cancer for a clinical trial. Dogs must be at least one year of age and greater than ten kilograms of body weight. For more information on this clinical trial, or to see if your dog is eligible for enrollment, please contact [email protected] or call 410-502-7325.
Learn more: Clinical trial flier | Clinical trial details handout

The Center for Image-Guided Animal Therapy is now recruiting dogs with mammary (breast) cancer for a Phase IB trial of a veterinary cryotherapy device. To find out more about this study, please contact Kubanda Cryotherapy at [email protected]. Learn more: Clinical trial flier

The Center for Image-Guided Animal Therapy is currently studying dilated cardiomyopathy and collecting pilot data on healthy Doberman Pinscher and Irish Wolfhound dogs. To find out more about this study, please contact CIGAT.
Learn more: Clinical trial flier

This canine hemangiosarcoma clinical trial is currently closed to new enrollment. For more information, please contact [email protected] or call 410-502-7325.

This clinical trial is complete and is NOT enrolling new patients. Select patients with lumps and bumps may be eligible for discounted treatment. For more information, please contact Kubanda Cryotherapy at [email protected].

To assess the effectiveness of cryoablation or an investigational immunotherapy to treat osteosarcoma of the appendicular skeleton. Cryoablation is a technique to freeze tumors that may kill the tumor, alleviate pain, and assist the body in rejecting cancer that has spread. Immunotherapy is used as a means to create an in-situ cancer vaccine towards the tumor. Either treatment is performed prior to amputation.

The cryotherapy or immunotherapy and imaging to look for cancer spread or metastasis is fully funded. Any medications our veterinarians prescribe to alleviate the side effects of the procedure, as well as follow-up imaging and blood tests will also be covered by the study. Amputation and chemotherapy are required and are not covered by the study.

Dogs of any breed, sex, and age are eligible for the study.

• The dog’s owner has the ability to understand and sign a written informed consent and is willing to comply with study protocol.
• Histopathological confirmation of osteosarcoma.
• Systemically healthy other than the diagnosis of osteosarcoma.
• No prior treatment for osteosarcoma or chemotherapy for other cancers.
• Ability to transport dog to CIGAT for treatment and follow-up visits
• Other restrictions may apply. Please call for details.

• Dogs who have previously received chemotherapy or other investigational agents.
• Dog who is participating in another study.
• Life-threatening medical or immunosuppressive illness unrelated to cancer.
• Evidence of serious systemic disorder or other condition that is clinically incompatible with the study.

Eligible dogs will receive a PET-CT scan and will receive cryotherapy alone or two doses of tumor-injected immunotherapy.  Amputation is required at approximately 2 weeks after treatment followed by chemotherapy.  CT or PET-CT scans will be obtained at 3, 6, and 12 months after treatment Further monitoring will be performed as deemed necessary by CIGAT veterinarians.

To assess the effectiveness of standard of care radiation therapy combined with chemotherapy dogs with suspected gliomas.  In people radiation therapy (RT) is combined with a chemotherapy given by mouth called tetrazolamide (TMZ) to treat glioblastoma.

The radiation therapy and chemotherapy will be fully funded. Any medications our veterinarians prescribe to alleviate the side effects of the procedure, as well as follow-up MRI imaging and blood tests will also be covered by the study.  Treatment for progression of disease is not covered by the study.

Dogs of any breed and sex are eligible for the study.

• The dog’s owner has the ability to understand and sign a written informed consent and is willing to comply with study protocol.
• Intra-axial brain tumor (suspect glioma) >1cm in size on MRI, restricted to one side of the brain.
• Age of at least 1 year.
• Ability to transport dog to CIGAT for radiation therapy and follow-up visits
• Other restrictions may apply. Please call for details.

• Anticipated life expectancy of less than 1 month.
• Previous or current oncological treatment of the brain tumor.
• Participation in another study.
• Evidence of serious systemic disorder or other condition that is clinically incompatible with the study.

Eligible dogs will receive a CT scan under general anesthesia for RT planning. RT will be performed on five consecutive workdays with concurrent administration of TMZ.  We will perform the follow-up MRI scans at various intervals up to 1 year after treatment free of charge. Further monitoring will be performed as deemed necessary by CIGAT veterinarians.

This is a clinical trial that will enroll a total of nine dogs in order to evaluate the effects of an FDA-approved investigative agent on dogs that have hemangiosarcoma (visceral and/or cutaneous). Safety and toxicology studies have been performed in healthy dogs. This is the first trial using the agent for treating canine hemangiosarcoma.

Eligible dogs will have undergone histopathologic evaluation of their tumor at their local veterinary hospital. Following visceral or cutaneous diagnosis of hemangiosarcoma, the patient may be considered for enrollment. Dogs should weigh more than 10 kg (22 lbs) to be eligible for participation and be older than 1 year of age. Preoperative medical records, radiographs, ultrasounds, complete blood counts, serum chemistries and urinalyses will help us determine if dogs are eligible for this trial. In addition, each pet owner must sign an informed consent form in order to participate in the clinical trial.

Participating dogs should meet the following criteria:

• The owner is willing to comply with all study procedures and be available for the duration of the study
• The patient should have no concurrent kidney, liver or heart disease, or problems with blood clotting
• The patient should have no heart-based tumors

1. Splenectomy or lobectomy or histopathologic confirmation - the surgery is not part of the study; the surgery and diagnostic fees are paid by the owner
2. After confirmation of hemangiosarcoma, the study will provide a PET-CT scan (whole body) to determine the dog's baseline tumor burden as well as a blood test to check for a mutation in the MDR1 gene
3. Dogs with metastatic tumors measured by PET-CT scan are eligible for enrollment
4. Chemotherapy: the first chemotherapy will be given within one week of the initial PET-CT scan. A second chemotherapy session will be given one week later. During week three, there will be no treatment. This cycle will be repeated two more times for a total of six chemotherapy sessions. Prior to every chemotherapy session, blood tests will be performed
5. Follow-up PET-CT scan will be performed after chemotherapy has finished
6. Once a month physical examination will be performed (this may include blood tests, radiographs and/or ultrasound) for 2-3 more visits after chemotherapy has concluded

Owners are responsible for their dog's initial surgery (workup). The study pays for all diagnostics and therapies that occur at the Center for Image-Guided Animal Therapy including the MDR1 genetic test, PET-CT scans, chemotherapy, lab work, and physical examinations.